文献速递消化道肿瘤与早癌消化内镜

绿茶提取物预防结直肠腺瘤:一项随机安慰剂对照临床试验结果

Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial.
PubMed 文献 · Am J Gastroenterol · 2022-02-25

在德国40个中心开展的随机双盲试验中,1001例结直肠腺瘤患者先经4周绿茶提取物导入期后按1:1随机分配至标准化含150 mg EGCG的绿茶提取物组(每日两次)或安慰剂组,干预3年。改良意向治疗人群(n=632)随访结肠镜检查腺瘤率安慰剂组55.7% vs 绿茶提取物组51.1%,差异无统计学意义(校正相对危险度0.905;P=0.1613)。绿茶提取物耐受性良好,但全研究人群两组腺瘤率无统计学显著差异。

要点

  • 绿茶提取物标准化至150 mg EGCG每日两次,干预3年,耐受性良好。
  • 改良意向治疗人群腺瘤率安慰剂组55.7% vs 绿茶提取物组51.1%,差异无统计学意义(校正相对危险度0.905;P=0.1613)。
  • 符合方案人群腺瘤率安慰剂组54.3%(151/278) vs 绿茶提取物组48.3%(129/267),差异无统计学意义(校正相对危险度0.883;P=0.1169)。

核心结论

  • 绿茶提取物耐受性良好,但全研究人群中绿茶提取物组与安慰剂组的腺瘤率无统计学显著差异。

研究设计与样本

  • 随机双盲安慰剂对照试验,在德国40个中心开展,1001例结直肠腺瘤患者入组,经4周绿茶提取物导入期安全评估后按1:1随机分配(n=879)。
  • 干预为标准化至150 mg EGCG的绿茶提取物每日两次 vs 安慰剂,持续3年;主要终点为随机化后3年随访结肠镜检查时腺瘤/结直肠癌的存在。

主要发现

  • 绿茶提取物安全性良好,两个均衡组间不良事件无重大差异。
  • 改良意向治疗人群(全部随机参与者即意向治疗人群且随机化后26-44个月有随访结肠镜检查;n=632)腺瘤率安慰剂组55.7% vs 绿茶提取物组51.1%,4.6%的差异无统计学意义(校正相对危险度0.905;P=0.1613)。
  • 符合方案人群腺瘤率安慰剂组54.3%(151/278) vs 绿茶提取物组48.3%(129/267),绿茶提取物组略低但无统计学意义(校正相对危险度0.883;P=0.1169)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Preclinical, epidemiological, and small clinical studies suggest that green tea extract (GTE) and its major active component epigallocatechingallate (EGCG) exhibit antineoplastic effects in the colorectum. METHODS: A randomized, double-blind trial of GTE standardized to 150 mg of EGCG b.i.d. vs placebo over 3 years was conducted to prevent colorectal adenomas (n = 1,001 with colon adenomas enrolled, 40 German centers). Randomization (1:1, n = 879) was performed after a 4-week run-in with GTE for safety assessment. The primary end point was the presence of adenoma/colorectal cancer at the follow-up colonoscopy 3 years after randomization. RESULTS: The safety profile of GTE was favorable with no major differences in adverse events between the 2 well-balanced groups. Adenoma rate in the modified intention-to-treat set (all randomized participants [intention-to-treat population] and a follow-up colonoscopy 26-44 months after randomization; n = 632) was 55.7% in the placebo and 51.1% in the GTE groups. This 4.6% difference was not statistically significant (adjusted relative risk 0.905; P = 0.1613). The respective figures for the per-protocol population were 54.3% (151/278) in the placebo group and 48.3% (129/267) in the GTE group, indicating a slightly lower adenoma rate in the GTE group, which was not significant (adjusted relative risk 0.883; P = 0.1169). DISCUSSION: GTE was well tolerated, but there was no statistically significant difference in the adenoma rate between the GTE and the placebo groups in the whole study population.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Seufferlein T, Ettrich TJ, Menzler S, et al. Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial. Am J Gastroenterol. 2022. PMID: 35213393. doi:10.14309/ajg.0000000000001706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。